Literature DB >> 9305600

Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

Y Matsuo1, R A MacLeod, C C Uphoff, H G Drexler, C Nishizaki, Y Katayama, G Kimura, N Fujii, E Omoto, M Harada, K Orita.   

Abstract

We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is associated with a minute chromosomal insertion, ins(11;9)(q23;p22p23). MOLM-13 and MOLM-14 are the first cell lines with, and represent the third reported case of, MLL gene rearrangement arising via chromosomal insertion. Both cell lines carry trisomy 8 which was also present during the MDS phase, as well as the most frequent trisomies associated with t(9;11), ie, +6, +13, +19 variously present in different subclones. Despite having these features in common, differences in antigen expression were noted between the two cell lines: that of MOLM-13 being CD34+, CD13-, CD14-, CD15+, CD33+; whereas MOLM-14 was CD4+, CD13+, CD14+, CD15+, CD33+. Differentiation to macrophage-like morphology could be induced in both cell lines after stimulation with INF-gamma alone, or in combination with TNF-alpha, which treatment also induced or upregulated, expression of certain myelomonocyte-associated antigens, including CD13, CD14, CD15, CD64, CD65 and CD87. Together, these data confirm that both cell lines are likely to be novel in vitro models for studying monocytic differentiation and leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305600     DOI: 10.1038/sj.leu.2400768

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  84 in total

1.  Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.

Authors:  Xiaochuan Yang; Amy Sexauer; Mark Levis
Journal:  Br J Haematol       Date:  2013-10-10       Impact factor: 6.998

2.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Authors:  Kensuke Kojima; Marina Konopleva; Ismael J Samudio; Masato Shikami; Maria Cabreira-Hansen; Teresa McQueen; Vivian Ruvolo; Twee Tsao; Zhihong Zeng; Lyubomir T Vassilev; Michael Andreeff
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

3.  Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.

Authors:  Lucy Swift; Aarthi Jayanthan; Yibing Ruan; Ronald Anderson; Jessica Boklan; Tanya Trippett; Aru Narendran
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

4.  Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.

Authors:  Mario P Tschan; Elena A Federzoni; Aladin Haimovici; Christian Britschgi; Bettina A Moser; Jing Jin; Venkateshwar A Reddy; Dennis A Sheeter; Kimberlee M Fischer; Peiqing Sun; Bruce E Torbett
Journal:  Biochim Biophys Acta       Date:  2015-07-15

5.  Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.

Authors:  Ellen Weisberg; Atsushi Nonami; Zhao Chen; Erik Nelson; Yongfei Chen; Feiyang Liu; HaeYeon Cho; Jianming Zhang; Martin Sattler; Constantine Mitsiades; Kwok-Kin Wong; Qingsong Liu; Nathanael S Gray; James D Griffin
Journal:  Clin Cancer Res       Date:  2014-09-03       Impact factor: 12.531

6.  Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.

Authors:  Yufei Chen; Patricia Ernst
Journal:  Cell Cycle       Date:  2019-06-04       Impact factor: 4.534

7.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

8.  Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.

Authors:  Jesse J McClure; Cheng Zhang; Elizabeth S Inks; Yuri K Peterson; Jiaying Li; C James Chou
Journal:  J Med Chem       Date:  2016-10-26       Impact factor: 7.446

9.  The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells.

Authors:  Christine M Palermo; Cecily A Bennett; Amanda C Winters; Charles S Hemenway
Journal:  Leuk Res       Date:  2007-09-17       Impact factor: 3.156

10.  In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.

Authors:  Peter G Miller; Fatima Al-Shahrour; Kimberly A Hartwell; Lisa P Chu; Marcus Järås; Rishi V Puram; Alexandre Puissant; Kevin P Callahan; John Ashton; Marie E McConkey; Luke P Poveromo; Glenn S Cowley; Michael G Kharas; Myriam Labelle; Sebastian Shterental; Joji Fujisaki; Lev Silberstein; Gabriela Alexe; Muhammad A Al-Hajj; Christopher A Shelton; Scott A Armstrong; David E Root; David T Scadden; Richard O Hynes; Siddhartha Mukherjee; Kimberly Stegmaier; Craig T Jordan; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2013-06-13       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.